Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma

To evaluate the complete clinical response rate according to the International Working Group criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients

r-chop
ibritumomab tiuxetan
zevalin
  • 19 views
  • 07 Nov, 2020
  • 1 location
Rituximab Combination Chemotherapy and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

them from dividing. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal

combination chemotherapy
rituximab
doxorubicin
cancer
follicular lymphoma
  • 19 views
  • 07 Nov, 2020
  • 1 location
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. Giving

  • 37 views
  • 26 Jan, 2021
  • 1 location